Diabetic Neuropathy Device™
One Device. Two Fibers. Zero Guesswork.
Embedded Files
✅ ALZHEIMER'S TESTING—$0 Down. Zero Risk.
Diabetic Peripheral Neuropathy
Diabetic Neuropathy is often silent—until it’s too late. The Diabetic Neuropathy Device™ (DND) changes that by offering the only FDA-registered solution that objectively assesses both small and large fiber nerve function at the point of care.
Unlike subjective pinprick tests or tuning forks, the DND delivers quantifiable data in 3-minutes or less—enabling early detection, documented medical necessity, and multi-visit therapy planning.
Temperature (Small Fiber)
Temperature (Small Fiber)
The Device (DND) Replaces Tuning Forks and Monofilaments...
The Device (DND) Replaces Tuning Forks and Monofilaments...
Kazu Suzuki DPM, Medical Director of the Tower Wound Care Center at the Cedars-Sinai Medical Towers in Los Angeles, CA; Managing Neuropathy And Pain In Wound Care Patients, Podiatry Today; September 2015; 26-27.
Site-Specific Predictive Biomarkers
Site-Specific Predictive Biomarkers
Vibration (Large Fiber)
Vibration (Large Fiber)
"Every medical practice should test patients with the DND before referring them to a specialist because it can help identify potential underlying conditions that may require further investigation or treatments." -J. Gonzalez MD, Neurologist
Comprehensive Foot Exams (Painful/Painless)
Comprehensive Foot Exams (Painful/Painless)
People with diabetes live longer, healthier lives with fewer complications thanks to technological advances that enable earlier identification and intervention. These innovations have revolutionized diabetes management, improving patient outcomes and quality of life. It is now essential, if not an obligation, for medical providers to adopt modern, objective diagnostic tools rather than relying on outdated methods such as tuning forks (invented in 1711) and monofilaments (invented in 1938). Diabetic neuropathy, a common and serious complication of diabetes, often leads to significant morbidity and mortality. The epidemiology and progression of this condition remain unclear, partly due to limitations in traditional diagnostic tools. Primary care providers are pivotal in the early detection of foot-related issues, as they are often the first point of contact for patients experiencing discomfort. By utilizing advanced, objective methods to diagnose neuropathy, providers can ensure timely interventions and reduce the risk of life-altering complications.
People with diabetes live longer, healthier lives with fewer complications thanks to technological advances that enable earlier identification and intervention. These innovations have revolutionized diabetes management, improving patient outcomes and quality of life. It is now essential, if not an obligation, for medical providers to adopt modern, objective diagnostic tools rather than relying on outdated methods such as tuning forks (invented in 1711) and monofilaments (invented in 1938). Diabetic neuropathy, a common and serious complication of diabetes, often leads to significant morbidity and mortality. The epidemiology and progression of this condition remain unclear, partly due to limitations in traditional diagnostic tools. Primary care providers are pivotal in the early detection of foot-related issues, as they are often the first point of contact for patients experiencing discomfort. By utilizing advanced, objective methods to diagnose neuropathy, providers can ensure timely interventions and reduce the risk of life-altering complications.
Get Reimbursed for Foot Exams
Monofilament testing, although affordable and widely used, is not without limitations. The perception that inexpensive tools like monofilaments are sufficient for diagnosing neuropathy can lead to delayed interventions and an increased risk of complications. A study published in the Journal of Diabetes Science and Technology highlighted that monofilaments have a sensitivity of only 64% for detecting diabetic peripheral neuropathy, raising concerns about their reliability. This underscores the need for more accurate and objective diagnostic methods to ensure early detection and better patient outcomes. Relying on subjective and outdated tools such as monofilaments or tuning forks risks false negatives that delay critical care and false positives that lead to unnecessary interventions. Medical providers must consider modern alternatives that improve diagnostic accuracy and qualify for reimbursements, ensuring better care and financial viability for clinics.
Diabetic and Non-Diabetic
The Diabetic Neuropathy Device™ (DND), introduced in 2014, represents a significant advancement in detecting and measuring neuropathy. Clinical studies demonstrate that the DND provides more precise and reliable results than traditional tools like monofilaments and tuning forks, which are prone to false positives and negatives.
With the DND, medical providers can standardize diabetic foot exams across the United States, ensuring consistent and effective patient care. This groundbreaking tool enables accurate diagnosis and monitoring of diabetic neuropathy, leading to timely treatments and improved outcomes. Recognized as the most significant innovation in diabetic neuropathy detection in over 80 years, the DND is a clinical necessity and eligible for reimbursement from Medicare, Medicaid, and commercial insurers.
Investing in the DND is an investment in better patient outcomes, reduced complications, and a modernized approach to neuropathy care. By adopting this innovative device, providers can elevate their standard of care and ensure that patients receive the best possible management for diabetic and non-diabetic neuropathy.
Diabetic Neuropathy Accounts for More Hospitalizations Than All Other Diabetic Complications Combined...
Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018
"The DND has improved the patient understanding of their disease, which is very helpful." - W. Beaton DPM
In the U.S., an estimated that up to 85% of lower extremity amputations among persons with diabetes can be prevented with improved foot care programs.
In the U.S., an estimated that up to 85% of lower extremity amputations among persons with diabetes can be prevented with improved foot care programs.
Bild DE, et al. Lower Extremity Amputations in People with Diabetes: Epidemiology and Prevention. Diabetes Care 1989; 12:24-31; CDC MMWR November 01, 1991 / 40(43);737-7
What Makes it Different:
What Makes it Different:
Dual-Fiber Detection
Detects both small (unmyelinated) and large (myelinated) nerve damage—critical for diabetic and prediabetic patients
Fully Objective & Non-Invasive
No guesswork, no pain—just reproducible results providers can trust
Medicare-Reimbursable
Valid CPT codes supported by strong clinical documentation
Testing in 3 Minutes or Less
Fits into your existing workflow without disrupting patient volume
Supports Amputation Prevention Protocols
Ideal for patients with diabetes, PAD, or CKD—before symptoms become irreversible
"We regularly use the Diabetic Neuropathy Device™ (DND) to monitor our diabetic patients who are at risk for developing diabetic neuropathy, as well as patients who are already diagnosed with diabetic neuropathy." -C. Soller NP, Endocrinology
Modern Technology
The Diabetic Neuropathy Device™ (DND) aligns with the latest screening and diagnostic recommendations from the American Diabetes Association (ADA). As the only tool capable of screening for distal symmetric polyneuropathy (DSPN) by assessing both temperature sensitivity (small fiber function) and vibration perception (large fiber function), the DND sets a new standard in neuropathy diagnostics, as emphasized in the ADA’s Diabetic Neuropathy: A Position Statement by the American Diabetes Association.
Tailored neuropathy treatments are essential to address each patient’s unique clinical presentation and underlying pathology while avoiding the risks associated with opioid use. For example, treating painful neuropathy with pain-relieving medications alone may mask loss of protective sensation (LOPS) in the feet, leaving patients vulnerable to foot ulcers and amputation. Early and accurate identification of neuropathy allows providers to intervene at the earliest stages of the condition, effectively reducing risk factors and improving outcomes.
By leveraging advanced tools like the DND, medical providers can enhance their ability to diagnose, monitor, and manage diabetic neuropathy, ultimately protecting patients from severe complications and improving their quality of life.
Don't Change Your Workflow, Just Your Tools!
Two Major Modalities in One Simple-to-Use Handheld Device
Two Major Modalities in One Simple-to-Use Handheld Device
Boris Golosarsky, MD MACP FACPI, Podiatry Management, Profiles in Excellence, January 2015
The DND objectively measures both small and large fiber neuropathy—enabling earlier detection, full nerve assessment, and more comprehensive diagnostics in one device.
"We use the DND because it gives us both the small and large fiber results that we feel are important for every diabetic patient." -R. Cardenas MD, Family Practice
Morbidity and Mortalities
Neuropathy is a serious condition that, if not accurately diagnosed and treated promptly, can lead to devastating outcomes, such as amputations of the toes, feet, or legs. The failure to adopt advanced diagnostic tools and procedures has resulted in medical institutions and physicians being held liable for malpractice. A landmark case, Washington v. Washington Hospital (1990)., set legal precedent in the U.S. regarding this issue.
To mitigate these risks, clinicians must stay informed about emerging best practices that are supported by clinical evidence. By adopting advanced technologies and emphasizing prevention, healthcare providers can improve patient outcomes while reducing the risk of complications. Proactive strategies, such as reallocating resources toward early detection and intervention, enable the administration of appropriate therapies. This approach can ultimately decrease the need for frequent inpatient and outpatient visits, significantly enhancing patients' quality of life.
"...by the time a patient fails the monofilament test, he or she may have a profoundly severe neuropathy, and it may be too late to intervene."
"...by the time a patient fails the monofilament test, he or she may have a profoundly severe neuropathy, and it may be too late to intervene."
Kazu Suzuki DPM, Medical Director of the Tower Wound Care Center at the Cedars-Sinai Medical Towers in Los Angeles, CA; Managing Neuropathy And Pain In Wound Care Patients, Podiatry Today; September 2015; 26-27.
Diabetic Neuropathy (DN) is Grossly Underdiagnosed and Undertreated.
Diabetic Neuropathy (DN) is Grossly Underdiagnosed and Undertreated.
Aaron Vinik, MD, PhD, FCP, MACP, FACE, et al, Endocrinologist, Diabetic Neuropathies, February 5, 2018
Identifying the following nerve fibers may increase earlier awareness and interventions:
Aα fibers are large myelinated fibers in charge of motor functions and muscle control.
Aβ fibers are large myelinated fibers with sensory functions such as perception to touch, vibration, and position.
Aδ fibers are small myelinated fibers in charge of pain stimuli and cold perception.
C fibers can be myelinated or unmyelinated and have sensory (warm perception and pain) and autonomic functions (blood pressure and heart rate regulation, sweating, etc.).
"One of the great advantages of using the DND on our diabetic patients who have started to develop diabetic neuropathy, is that showing them their results, often makes the consequences of not taking care of themselves more realistic." -S. Erle DC, Neuropathy Centers
Importance of Specificity
Diabetics that have lower-extremity amputations have lifespans that range between 40% mortality in 1-year, 65% mortality in 3-years, and 80% mortality in 5-years. Diabetic Neuropathy is a serious diabetes complication affecting as many as 50% of people who suffer from pain, and another 50% may be asymptomatic - who are at the highest risk of falls, ulcerations, and amputations. Nerve damage and poor circulation are the most common causes of diabetic foot problems. One of the most underdiagnosed and untreated parts of a comprehensive foot exam is checking the loss of protective sensation (LOPS) in the feet. The diabetic large nerve fiber dysfunction, as measured by vibration, predicts foot ulcerations, amputations, and mortality.
(Painless) Diabetic large nerve fiber dysfunction as measured by vibration Predicts foot ulceration, amputation and mortality.
(Painless) Diabetic large nerve fiber dysfunction as measured by vibration Predicts foot ulceration, amputation and mortality.
https://care.diabetesjournals.org/content/32/10/1896
The purpose of a comprehensive diabetic foot exam is to gather as much clinical data about the condition of a person's normal or abnormal condition in the feet of both large and small nerve fibers. A diabetic foot exam also checks people with diabetes for infection, injury, and bone abnormalities. However, over 99% of all medical providers use outdated and subjective tools (tuning fork, invented in 1711 or monofilaments, invented in 1938) to identify a progressive disease. Distal Symmetric Polyneuropathy (DSPN), a glove and stocking distribution, is the most common form of Diabetic Neuropathy (DN) and is recognized as the most troublesome complication of diabetes mellitus leading to the greatest morbidity and mortality, which accounts for the most amount of hospitalizations than all other diabetic complications combined and is responsible for up to 75% of non-traumatic amputations.
(Painful) Diabetic small fiber neuropathy can only be verified with thermal thresholds or skin biopsies.
(Painful) Diabetic small fiber neuropathy can only be verified with thermal thresholds or skin biopsies.
Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018
The proper diagnosis of diabetic neuropathy should require tools to identify and measure the disorder quantitatively for the different abnormalities that occur to specific nerve fibers. Combining at least two different examinations (large and small fiber) will increase the sensitivity and specificity of detecting DPN. Currently, many medical providers are unaware of reimbursable tools that address both large fiber and small fiber neuropathy, both of which manifest in patients with diabetes. The Diabetic Neuropathy Device™ is the first FDA Cleared multi-objective tool with 15 measurements that identify both large and small nerve fibers in the upper and lower extremities.
"It is imperative that we use our ability to measure quantitatively the different types of defects that occur in the disorder (DN), so the appropriate therapies can be targeted to specific nerve fiber types."
"It is imperative that we use our ability to measure quantitatively the different types of defects that occur in the disorder (DN), so the appropriate therapies can be targeted to specific nerve fiber types."
Aaron Vinik, MD, PhD, FCP, MACP, FACE, et al, Endocrinologist, Diabetic Neuropathies, February 5, 2018
Mechanism of Action
Mechanism of Action
Skin is the largest organ of the body and helps regulate body temperatures and permits touch, heat, and cold sensations. The mechanism of action in identifying nerve fibers may be performed by testing the autonomic nervous system's sudomotor function using the sympathetic skin response (SSR). The SSR specifically tests sudomotor skin fibers that do not participate in thermoregulatory sweating. This methodology is currently performed using monofilaments and tuning forks and is recognized by multiple organizations around the U.S. including the American Diabetes Association (ADA) to diagnose autonomic dysfunction with polyneuropathies. Small fiber peripheral neuropathy primarily or exclusively affects the body, such as the skin and those that mediate pain and thermal sensation.
Skin is the largest organ of the body and helps regulate body temperatures and permits touch, heat, and cold sensations. The mechanism of action in identifying nerve fibers may be performed by testing the autonomic nervous system's sudomotor function using the sympathetic skin response (SSR). The SSR specifically tests sudomotor skin fibers that do not participate in thermoregulatory sweating. This methodology is currently performed using monofilaments and tuning forks and is recognized by multiple organizations around the U.S. including the American Diabetes Association (ADA) to diagnose autonomic dysfunction with polyneuropathies. Small fiber peripheral neuropathy primarily or exclusively affects the body, such as the skin and those that mediate pain and thermal sensation.
The sympathetic skin response is a simple, reproducible, and non-invasive test based on modifying the skin potential of peripheral nerves. Sympathetic skin response has been used to diagnose polyneuropathy, erectile dysfunction, central degenerative diseases, multiple sclerosis, brain infarction, reflex sympathetic dystrophies, spinal, and peripheral nerve lesions. The Diabetic Neuropathy Device™ is a modern tool that uses the SSR to help patients discriminate against variable temperature and vibration stimuli.
Quantitative Sensory Testing (QST) and Sympathetic Skin Response tests (SSR) are distinct diagnostic procedures employed to assess the nervous system: QST focuses on evaluating sensory function by measuring the perception of stimuli, including touch, temperature, and pressure, commonly used in neurology to assess peripheral neuropathy; whereas SSR assesses the sympathetic nervous system's activity by measuring changes in skin conductance in response to stress or stimuli, often applied in neurology to evaluate autonomic nervous system function, with key differences lying in their respective focuses, stimuli application methods, and measurements. Multiple studies have proven the value of Quantitative Sensory Testing (QST) measures in the detection of subclinical neuropathy (small fiber neuropathy), the assessment of the progression of neuropathy, and the prediction of the risk of foot ulceration (117,129,130). These standardized measures of vibration and thermal thresholds also play an important role as primary efficacy endpoints in multicenter clinical trials.
Do you want to improve your patient services but lack the financial resources to get started? Click here to discuss potential collaborations and opportunities.
Clinical References (use dropdown)
Rolke R, Magerl W, Campbell KA, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006; 123(3):231-243.
M.Backonja. Challenges and opportunities for neuropathic pain evaluation in a primary care setting. Third International Congress on Neuropathic Pain. Athens, Greece. 2010:18. Personal communication.
M.Ware. Standardizing the clinical sensory examination. Third International Congress on Neuropathic Pain. Athens, Greece. 2010:18. Personal communication.
G. Mick. Basis for a simple clinical sensory examination in non-specialized practice. Third International Congress on Neuropathic Pain. Athens, Greece. 2010:18. Personal communication.
Boulton AJ,Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by American Diabetes Association. Diabetes Care 2005; 28:956.
http://uptodateonline.com/online/content/topic.do?key=neuropat
Petr Boucek Advanced Diabetic Neuropathy: A Point of no Return? Rev Diabet Stud, 2006, 3(3):143-150.
M. Bharara, MsC, j.e. Cobb, PhD, CEng, and D.J. Claremont, MSc, DPhil, FIPEM
Thermography and Thermometry in the Assessment of Diabetic Neuropathic Foot: A Case for Furthering the Role of Thermal Techniques. Int J Low Extem Wound5(4); 2006pp. 250-260.
Dworkin, RH., editor. Recommendations for the definition, assessment, and pharmacologic management of neuropathic pain. Am J Medicine. 2009; 122:10A (suppl): S1-S31.
Treede RD, Jensen TS, Campbell JN, et. Neuropathic pain: redefinition and a grading system for clinical research purposes. Neurology. 2008; 70: 1630-1635.
National Institute of Health. http://diabetes.niddk.nih.gov/dm/pubs/neuropathies/.
Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008; 136(3):380-387.
Kanji JN, Anglin RE, Hunt DI., et al. JAMA 2010;303(15):1526-1532
Valk, GD,Grootenhuis J TH, Bouter LM., et al. Methods for assessing diabetic polyneuropathy:validity and reproducibility of the measurement of sensory symptom severity and nerve tests. Diabetes research and Clinical practice 2000: 47;87-95.
Vinik AI, Bril V, Litchy WJ, Price KL, Bastyr EJ. Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. MBBQ Study Group. Muscle Nerve 2005. 32:619-625 .
DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995. 122(8):561-568.
Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic on health-related quality of life: review and implications. Neurology 20007;68(15):1178-1182.
Dworkin RH, O’Connor AB, Audette J, et al. Recommendation for the pharmacological management of neuropathic pain: an overview and literature update. Update on guidelines for the treatment of neuropathic pain, including consideration for special population. Mayo Clin Proc. 2010; 85 (3) (suppl): S3-S14.
http://www.disabled-world.com/health/diabetes/diabetic-foot-ulcers.php
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Centers for Disease Control and Prevention, National Diabetes Fact Sheet, 2011
Guy RJC, Clark CA, Malcolm PN, Watkins PJ: Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 28: 131–137, 1985.
Vinik AI, Erbas T, Stansberry KB, et al. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109:451–73
Katims JJ. Electrodiagnostic functional sensory evaluation of the patient with pain: A review of the neuroselective current perception threshold (CPT) and pain tolerance threshold (PTT). Pain Digest. 1998;8:219–30.
Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983 46: 491–499
Dyck PJ, Zimmerman IR, O'Brien PC, Ness A, Caskey PE, Karnes J, Bushek W) Introduction of automated systems to evaluate touch-pressure, vibration, and thermal cutaneous sensation in man. Ann Neurol 1983 4: 502–510
Fruhstorfer H, Lindblom U, Schmidt WG) Method for quantitive estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976 39: 1071–1075
Fagius J, Wahren LK) Variability of sensory threshold determinations in clinical use. J Neurol Sci 1981 51: 11–27
Bloom S, Till S, Sönksen P, Smith S) Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J 1984 288: 1793–1795
Bergström B, Rosberg K, Sundkvist G Autonomic nerve function tests. Reference values in healthy subjects. Clin Physiol 1986 6:523–528
Scott AR, MacDonald IA, Bennett T, Tattersall RB) Abnormal thermoregulation in diabetic autonomic neuropathy. Diabetes 3 1988 7:961–968
Vinik AI, Erbas T, Stansberry KB, et al. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109:451–73
Ohta Akio, Obi Ryusei, Kawata Takehiro, et al. The cold-loaded pain sensation test in the diagnosis of diabetic neuropathy. Jpn J Clin Physiol. 2006;36:47–55.
Masson EA, Boulton AJM. The neurometer: validation and comparison with conventional tests for diabetic neuropathy. Diabetic Med. 1991;8:s63–6
Pitei DL, Watkins PJ, Stevens MJ, et al. The value of the neurometer in assessing diabetic neuropathy by measurement of the current perception threshold. Diabetic Med. 1994;11:872–6.
Suzuki K, Chung Y, Kobayashi Y, et al. Current perception thresholds: a new method for assessment of peripheral sensory neuropathy in diabetes mellitus. Peripheral Nerve. 1995;6:59–63.
Parkhouse N, LeQueen PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med 1988;318:1306–1309
Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med. 1995;12:566–579
Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J: Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol 2005,10(5):24
Pajouhi M, Shaban Nejad Khas Z, Mohajeri Tehrani M: Evaluation and prevention of diabetic neuropathy (review article). TUMJ2007,65(3):1–6.
Birke J, Rolfsen R: Evaluation of a self-administered sensory testing tool to identify patients at risk of diabetes-related foot. Diab Care1998, 21:23–25
Litzelman D, Marriott D, Vinicor F: Independent physiological predictors of foot lesions in patients with NIDDM. Diab Care 1997, 20:1273–1278
Olaleye D, Perkins BA, Bril V: Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diab Res Clin Prac 2001,54(2):115–128
Nather A, Neo S, Chionh S, Liew S, Sim E, Chew J: Assessment of sensory neuropathy in diabetic patients without diabetic foot problems. J Diabetes Complications 2008,22(2):126–131 Abbott AL, Carrington H, Ashe S, Bath LC, Every J, Griffiths ER, Van Ross AJM: Boulton, North–west diabetes foot care study: incidence of and risk factors for new diabetic foot ulceration in a community-based study. Diab Med 2002, 19:377–384.
Forouzandeh F, Aziz Ahari A, Abolhasani F, Larijani B: Comparison of different screening tests for detecting diabetic foot neuropathy.Acta Neurologica Scandinavica 2005,112(6):409–413.
Dimitrakoudis D, Bril V: Comparison of sensory testing on different toe surfaces: implications for neuropathy screening. Neurology2002,59(4):611–613
Armstrong DG1, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG.Arch Intern Med. 1998 Feb 9;158(3):289-92.Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.
Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial.Pham H1.Diabetes Care. 2000 May;23(5):606-11.
Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2Painful diabetic neuropathy: an update.,*Ann Neurosci. 2011 Oct; 18(4): 168–175. 10.5214/ans.0972-7531.1118409
Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2 Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM22003 Aug;26(8):2305-10.
Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2 Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2
Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2 Risk factors for foot ulceration in adults with end-stage renal disease on dialysis: study protocol for a prospective observational cohort study. 2015 Sep 18;8:53. doi: 10.1186/s13047-015-0110-9. eCollection 2015. The Thermal Sensitivity Test in Evaluating Outcome after Peripheral Nerve Injury .Biomed Res Int. 2015; 2015: 528356.Published online 2015 Jun 23.
Sharonjeet Kaur,1 Promila Pandhi,1 and Pinaki Dutta, DM2 New diagnostic tests for diabetic distal symmetric polyneuropathy. 2011 Jan-Feb;25(1):44-51.
Arezzo JC, Schaumburg HH, Laudadio C Thermal sensitivity tester. Device for quantitative assessment of thermal sense in diabetic neuropathy.1986 Diabetes 35:590–592.
Bertelsmann FW, Heimans JJ, Weber EJ, van der Veen EA, Schouten JA Thermal discrimination thresholds in normal subjects and in patients with diabetic neuropathy. J Neurol Neurosurg Psychiatry.1985 48:686–690.
Claus D, Hilz MJ, Neundorfer Thermal discrimination thresholds: a comparison of different methods. Acta Neurol Scan B.1990 81:533–540.
Harding LM, Loescher AR Adaptation to warming but not cooling at slow rates of stimulus change in thermal threshold measurements. 2005 Somatosens Mot Res 22:45–48.
Hoitsma E, Reulen JP, de Baets M, Drent M, Spaans F, Faber CG . Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004 227:119–130.
Ijff GA, Bertelsmann FW, Nauta JJ, Heimans JJ Cold and warm cutaneous sensation in diabetic patients. Diabet Med 1991:8:S71–73.
Kenshalo DR, Bergen). A device to measure cutaneous temperature sensitivity in humans and subhuman species. J Appl Physiol DC 1975: 39:1038–1040.
Lin YH, Hsieh SC, Chao CC, Chang YC, Hsieh ST . Influence of aging on thermal and vibratory thresholds of quantitative sensory testing. J Peripher Nerv Syst 2005 10:269–281.
Maser RE, Nielsen VK, Bass EB, Manjoo Q, Dorman JS, Kelsey SF, Becker DJ, Orchard TJ (). Measuring diabetic neuropathy. Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989 12:270–275.
Palmer ST, Martin DJ, Steedman WM, Ravey J C- and Adelta-fibre mediated thermal perception: response to rate of temperature change using method of limits. Somatosens Mot Res 2000 17:325–333.
Yarnitsky D, Sprecher Thermal testing: normative data and repeatability for various test algorithms. J Neurol Sci E 1994. 125:39–45.
Thermal discrimination and Weber's law: with a theory on the nature and function of sensory adaptation. Culler, E. A.Archives of Psychology, Vol 13, 81, 1926, . Sense of Touch and Common Feeling. E.H.Weber 1846
Golosarsky B. Can Heart Rate Variability timing reflect the body stress? 2006 Medical Hypothesis, V. 67, 1467-146
Golosarsky B. Making Neuropathy Screening exam Truly Comprehensive in 5 minutes. Profiles in Excellence. Podiatry Management, 2015 January 155-156
Golosarsky B., et al. 2013 U.S. Patent 8,579,830 Neuropathy Diagnostic Device.
Golosarsky, B., et al. Patent Office, Japan 2011-518739 Neuropathy Diagnostic Device.
Bakkers M1, Faber CG, Peters MJ, Reulen JP, Franssen H, Fischer TZ, Merkies IS Temperature threshold testing: a systematic review. J Peripher Nerv Syst. 2013 Mar;18(1):7-18
Metin Yavuz M, D.Eng, D.G. Armstrong , DPM, MD, PhD, et al; Temperature as a Causative Factor in Diabetic Foot Ulceration: A Call to Revisit Ulcer Pathomechanics; Journal of the American Podiatric Medical Association 2018
The Best Supplement that Scientific Thinking Can Offer for Nerve Health.*
People with diabetes are living longer and healthier lives with fewer complications because of technological advances, earlier interventions, and, in some cases, all-natural supplements like Dr. A. Vinik MD PhD nerve health supplements.
NutriNerve® is a proprietary formula created by the renowned Endocrinologist Dr. Aaron Vinik MD PhD. After many decades of scientific research in diabetic neuropathy, Dr. Vinik demonstrated that damaged nerves may be regenerated with the proper nutrients.
Click HERE for professional pricing.
Better Options
Better Options
Page updated
Report abuse